{"id":3204,"date":"2013-11-06T10:00:00","date_gmt":"2013-11-06T10:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-expands-the-novel-study-in-the-usa\/"},"modified":"2013-11-06T10:00:00","modified_gmt":"2013-11-06T10:00:00","slug":"xvivo-expands-the-novel-study-in-the-usa","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/","title":{"rendered":"XVIVO expands the NOVEL study in the USA"},"content":{"rendered":"
The University of Washington, Seattle, one of the major American lung transplant clinics, has been included in the American NOVEL study. It is the third clinic to have bought an XPS for this purpose. There continues to be great interest in the STEEN Solution\u2122 method and the XPS\u2122 in the USA.<\/strong><\/div>\n

XVIVO Perfusion AB (publ) was given approval by the FDA in the previous quarter to increase the number of centers in the ongoing NOVEL study in the USA. The participation of the University of Washington in Seattle in the NOVEL study will lead to more patients with lung disease now being able to receive a transplant.<\/span><\/p>\n

The NOVEL trial was designed to safely increase the percentage of usable lungs from the donor pool. It is being performed at 8 centers in the USA. In the study, clinical outcomes after transplantation of lungs that have undergone warm perfusion after having been initially discarded are compared with a control group consisting of lungs that were initially assessed to be usable. Up until now 54 patients in the NOVEL study have received transplants after warm perfusion using the STEEN Solution\u2122 method. The results so far from the study indicate that lungs evaluated using STEEN Solution\u2122 in an XPS\u2122 do not differ in terms of safety and function from lungs transplanted directly. These results thus indicate that more donated lungs will be able to be used safely for transplantation, and this will benefit patients on the waiting list for new lungs. These results are consistent with those published from centers in Canada and Europe that have used STEEN Solution\u2122 clinically using an equivalent technique.<\/span><\/p>\n

"We can see that there is growing interest in and outside the USA for the company\u2019s technology for warm perfusion using STEEN Solution\u2122 and XPS\u2122 as clinical experience becomes more widespread. It is exciting that leading clinics\u2019 interest is so great that they are investing considerable sums of money in equipment in order to be able to join the NOVEL study. They are doing so to be able to give transplants to more patients with severe lung disease," says Dr Magnus Nilsson, CEO of XVIVO Perfusion. <\/span><\/p>\n

November 6, 2013
Gothenburg
XVIVO Perfusion AB (publ)<\/span><\/p>\n

\n

For further information please contact:
<\/span>
Christoffer Rosenblad, CFO, +46 31\u00a0788 21 59, christoffer.rosenblad@xvivoperfusion.com<\/a><\/span>
For further information on XVIVO Perfusion\u2019s business, please refer to the company\u2019s website, www.xvivoperfusion.com<\/a><\/span><\/p>\n

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and\/or the Financial Instruments Trading Act. The information was submitted for publication on\u00a0November 6, 2013\u00a0at 11:00 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The University of Washington, Seattle, one of the major American lung transplant clinics, has been included in the American NOVEL…<\/p>\n","protected":false},"template":"","class_list":["post-3204","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml"],"acf":[],"yoast_head":"\nXVIVO expands the NOVEL study in the USA - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO expands the NOVEL study in the USA - XVIVO\" \/>\n<meta property=\"og:description\" content=\"The University of Washington, Seattle, one of the major American lung transplant clinics, has been included in the American NOVEL...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-expands-the-novel-study-in-the-usa\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-expands-the-novel-study-in-the-usa\\\/\",\"name\":\"XVIVO expands the NOVEL study in the USA - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-11-06T10:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-expands-the-novel-study-in-the-usa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-expands-the-novel-study-in-the-usa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-expands-the-novel-study-in-the-usa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO expands the NOVEL study in the USA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO expands the NOVEL study in the USA - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO expands the NOVEL study in the USA - XVIVO","og_description":"The University of Washington, Seattle, one of the major American lung transplant clinics, has been included in the American NOVEL...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/","name":"XVIVO expands the NOVEL study in the USA - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-11-06T10:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-expands-the-novel-study-in-the-usa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO expands the NOVEL study in the USA"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}